1Y Close · As of Aug 26, 2026
iNtRON Biotechnology operates in the Pharmaceuticals sector.
Legal name: iNtRON Biotechnology, Inc.
In fiscal year 2025, iNtRON Biotechnology (048530) reported revenue of 5.7 billion KRW, down 10.6% from 6.4 billion KRW a year earlier.
Operating profit was -7.9 billion KRW and net income was -9.0 billion KRW in the same year.
As of the Aug 26, 2026 close, the market capitalization was 87.0 billion KRW, with a P/B of 1.24.
These figures can be verified in the DART filing (receipt no. 20260311004106).
Financials
| Year | Rev | Op Inc | Net Inc |
|---|---|---|---|
| 2025 | 5.7B | -7.9B | -9.0B |
| 2024 | 6.4B | -5.2B | -2.6B |
| 2023 | 9.6B | -3.3B | -9.7B |
Checks
2 of 8 checked items currently applicable.
Market Cap & Price: Market cap is above the delisting threshold.
Audit Opinion: Audit opinion: Unqualified (clean).
Capital Increase: No capital-increase filings in the last 180 days.
Treasury Stock: Treasury stock filings in the last 3 years: 1 cancellation(s).
Embezzlement & Litigation: No embezzlement or litigation filings in the last 180 days.
Major Shareholder Change: No major shareholder changes in the last 180 days.
Market Action: No market actions recorded in the last 180 days.
Recent Filings
| Date | Filing |
|---|---|
| 2026-08-27 | Large Shareholding Report (General) |
| 2026-08-14 | Semi-Annual Report (2026.06) |